ABVC BioPharma
ABVC
9 hedge funds and large institutions have $156K invested in ABVC BioPharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.01% more ownership
Funds ownership: 1.83% → 1.84% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
9% less capital invested
Capital invested by funds: $171K → $156K (-$14.7K)
18% less funds holding
Funds holding: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$8.95K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$3.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$128 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $48.9K | +$11.8K | +16,382 | +30% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $32.1K | – | – | – |
|
|
APP
3
Avantax Planning Partners
Dubuque,
Iowa
| $26.7K | – | – | – |
|
|
XT
4
XTX Topco
George Town,
Cayman Islands
| $16K | +$3.22K | +4,461 | +24% |
|
5
Northern Trust
Chicago,
Illinois
| $13.1K | – | – | – |
|
6
State Street
Boston,
Massachusetts
| $8.82K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $8.47K | +$8.95K | +12,397 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1.79K | -$17 | -23 | -0.9% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $53 | -$128 | -178 | -70% |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$19.5K | -25,212 | Closed |
|
ABVC Hedge Fund Activity: Q3 2024 in Review
9 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2024, worth a combined $156K — down 8.6% from $171K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ABVC and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $11.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.5K sold.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $156K of ABVC BioPharma stock for Q3 2024, down 8.6% quarter-over-quarter.
- 1 fund opened new ABVC BioPharma positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest ABVC BioPharma buyer in Q3 2024 was Geode Capital Management, an estimated $11.8K added.
- The largest ABVC BioPharma seller in Q3 2024 was Citadel Advisors, an estimated $19.5K sold.
Based on aggregated 13F filings for Q3 2024.